MAM
WPP’s Wunderman acquires Bridge Worldwide
MUMBAI: WPP Group’s Wunderman has acquired marketing and interactive agency Bridge Worldwide (‘Bridge’), which is a Cincinnati-based interactive relationship marketing agency specialising in Fortune 100 consumer packaged goods and healthcare.
The acquisition of Bridge enhances Wunderman’s online and healthcare expertise and continues WPP’s strategy of developing its networks in fast growing markets and sectors.
AdMedia Partners, a New York investment bank specialising in mergers and acquisitions advisory services to the advertising and marketing, media, and related online and information services businesses, represented Bridge Worldwide in the acquisition.
“Bridge pioneered the use of the internet to establish active ongoing relationships between major consumer brands and their customers. The acquisition reflects Wunderman’s understanding of the importance of this new way to serve CPG clients, said Seth Alpert, one of the investment bankers who led Bridge’s deal team.
Leveraging the Internet as the hub of many of its programs, Bridge Worldwide’s results-driven creative has built consumer relationships for some of the world’s best known brands, including the CPG leader Procter & Gamble.
Bridge Worldwide will have access to the diverse resources of Wunderman’s global network; however, it will operate as an independent unit of Wunderman. Terms of the financial agreement were not disclosed.
“Bridge Worldwide’s depth of online and healthcare experience complements Wunderman’s, and we both share the same philosophies about the power of customer relationships and online dialog,” said Wunderman chairman and CEO Daniel Morel.
Bridge Worldwide, headquartered in Cincinnati, Ohio, employs more than 120 people and was named as one of the fastest growing companies in the city.
Bridge Worldwide president and CEO Jay Woffington said, “We are very excited to join WPP and be affiliated with a world-class organization such as Wunderman. This move allows us to tap into the expertise and the global scale of the network while maintaining our entrepreneurial culture and our flexible creative and strategic approach for our clients.”
Bridge’s audited revenues for the year ended 31 December 2004 were $10.2 million with net assets at completion of $1.8 million.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
